Reverse hydroxamate derivatives as metalloprotease inhibitors
CA 2281664 A1 · Owner: Wiethe, Robert William · Inventors: Wiethe, Robert William; Andersen, Marc W.; Andrews, Robert Carl
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A family of compounds having general structural formula (I) wherein W is a reverse hydroxamic acid group (a); R5 is hydrogen or lower alkyl; R6 is (b); where Z1 is heteroarylene; preferably: R1 is methyl ethyl, isopropyl, n-, propyl or 3,3,3-trifluoro-n-propyl; R2 is isobutyl or sec-butyl; R3 is hydrogen; R4 is tert-butyl, sec-butyl, 1-methoxy-1-ethyl or 2-(2pyridylcarbonylamino)-1-ethyl; R5 is hydrogen; and R6 is 2-thiazolyl or 2pyridyl. Such compounds show potent inhibition of MMP's cell-free TNF , convertase enzyme and TNF release from cells and in some cases inhibit TNF , convertase and TNF release from cells in preference to matrix metalloproteases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 24, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 24, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 24, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.